Bruton's tyrosine kinase inhibition suppresses pathological retinal angiogenesis

Documenti analoghi

• Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673
  di: Yue Wu, et al.
  Pubblicazione: (2024)
• Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases
  di: Henning Olbrich, et al.
  Pubblicazione: (2026)
• Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First‐in‐human, randomized, ascending‐dose studies
  di: Yuji Kumagai, et al.
  Pubblicazione: (2025)
• Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database
  di: Zeng‐Xiang Zhao, et al.
  Pubblicazione: (2024)
• Formulation breakthroughs driving broader tyrosine kinase use
  di: Hans Lennernäs, et al.
  Pubblicazione: (2026)